A detailed history of Israel Englander (Millennium Management LLC) transactions in Ironwood Pharmaceuticals Inc stock. As of the latest transaction made, Millennium Management LLC holds 925,872 shares of IRWD stock, worth $4.27 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
925,872
Previous 1,328,760 30.32%
Holding current value
$4.27 Million
Previous $8.66 Million 56.08%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$3.93 - $7.04 $1.58 Million - $2.84 Million
-402,888 Reduced 30.32%
925,872 $3.81 Million
Q2 2024

Aug 14, 2024

BUY
$5.58 - $8.61 $4.84 Million - $7.47 Million
867,316 Added 187.96%
1,328,760 $8.66 Million
Q1 2024

May 15, 2024

SELL
$8.32 - $15.45 $4.25 Million - $7.89 Million
-510,691 Reduced 52.53%
461,444 $4.02 Million
Q4 2023

Feb 14, 2024

BUY
$8.79 - $11.51 $6.3 Million - $8.25 Million
717,066 Added 281.13%
972,135 $11.1 Million
Q2 2023

Aug 14, 2023

SELL
$10.1 - $11.6 $11.4 Million - $13.1 Million
-1,127,479 Reduced 81.55%
255,069 $2.71 Million
Q1 2023

May 15, 2023

SELL
$10.37 - $12.56 $27 Million - $32.7 Million
-2,607,394 Reduced 65.35%
1,382,548 $14.5 Million
Q4 2022

Feb 14, 2023

BUY
$9.9 - $12.43 $21.6 Million - $27.2 Million
2,184,767 Added 121.03%
3,989,942 $49.4 Million
Q3 2022

Nov 14, 2022

BUY
$10.14 - $12.38 $7.34 Million - $8.97 Million
724,203 Added 67.0%
1,805,175 $18.7 Million
Q2 2022

Aug 15, 2022

BUY
$11.05 - $12.72 $318,880 - $367,073
28,858 Added 2.74%
1,080,972 $12.5 Million
Q1 2022

May 16, 2022

SELL
$10.61 - $12.88 $5.71 Million - $6.93 Million
-537,702 Reduced 33.82%
1,052,114 $13.2 Million
Q4 2021

Feb 14, 2022

BUY
$10.86 - $13.95 $481,467 - $618,459
44,334 Added 2.87%
1,589,816 $18.5 Million
Q3 2021

Nov 15, 2021

SELL
$11.92 - $13.92 $2.54 Million - $2.97 Million
-213,471 Reduced 12.14%
1,545,482 $20.2 Million
Q2 2021

Aug 16, 2021

BUY
$10.16 - $13.11 $7.88 Million - $10.2 Million
775,496 Added 78.85%
1,758,953 $22.6 Million
Q1 2021

May 17, 2021

BUY
$9.04 - $11.86 $1.14 Million - $1.5 Million
126,422 Added 14.75%
983,457 $11 Million
Q4 2020

Feb 16, 2021

BUY
$9.05 - $12.2 $7.05 Million - $9.5 Million
778,749 Added 994.75%
857,035 $9.76 Million
Q3 2020

Nov 16, 2020

SELL
$8.99 - $10.74 $2.09 Million - $2.49 Million
-232,012 Reduced 74.77%
78,286 $704,000
Q2 2020

Aug 14, 2020

BUY
$9.14 - $11.97 $2.62 Million - $3.43 Million
286,318 Added 1193.99%
310,298 $3.2 Million
Q1 2020

May 14, 2020

SELL
$8.58 - $14.01 $5.53 Million - $9.04 Million
-644,937 Reduced 96.42%
23,980 $242,000
Q4 2019

Feb 14, 2020

SELL
$8.22 - $14.0 $2.98 Million - $5.07 Million
-362,381 Reduced 35.14%
668,917 $8.9 Million
Q3 2019

Nov 14, 2019

BUY
$8.59 - $10.96 $5.58 Million - $7.12 Million
649,831 Added 170.35%
1,031,298 $8.85 Million
Q2 2019

Aug 15, 2019

BUY
$9.8 - $12.89 $3.57 Million - $4.69 Million
363,821 Added 2061.78%
381,467 $4.17 Million
Q2 2019

Aug 14, 2019

SELL
$9.8 - $12.89 $8.33 Million - $11 Million
-850,412 Reduced 97.97%
17,646 $242,000
Q1 2019

May 14, 2019

SELL
$8.27 - $12.73 $4.18 Million - $6.43 Million
-505,022 Reduced 36.78%
868,058 $11.7 Million
Q4 2018

Feb 14, 2019

BUY
$7.8 - $16.13 $8.67 Million - $17.9 Million
1,111,814 Added 425.55%
1,373,080 $14.2 Million
Q3 2018

Nov 14, 2018

BUY
$14.31 - $17.65 $2.78 Million - $3.42 Million
193,961 Added 288.18%
261,266 $4.82 Million
Q2 2018

Aug 14, 2018

BUY
$11.83 - $16.2 $796,218 - $1.09 Million
67,305 New
67,305 $1.29 Million
Q1 2018

May 15, 2018

SELL
$11.13 - $13.63 $272,295 - $333,457
-24,465 Closed
0 $0
Q4 2017

Feb 14, 2018

BUY
$12.16 - $14.58 $297,494 - $356,699
24,465
24,465 $367,000

Others Institutions Holding IRWD

About IRONWOOD PHARMACEUTICALS INC


  • Ticker IRWD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 153,231,008
  • Market Cap $706M
  • Description
  • Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...
More about IRWD
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.